The natural history of symptomatic uncomplicated diverticular disease: a long-term follow-up study.
Symptomatic uncomplicated diverticular disease
acute diverticulitis
outcome
quality of life
Journal
Annals of gastroenterology
ISSN: 1108-7471
Titre abrégé: Ann Gastroenterol
Pays: Greece
ID NLM: 101121847
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
06
2020
accepted:
09
09
2020
entrez:
3
3
2021
pubmed:
4
3
2021
medline:
4
3
2021
Statut:
ppublish
Résumé
Symptomatic uncomplicated diverticular disease (SUDD) affects about 20% of patients who have diverticulosis. However, the natural history of SUDD is not yet completely understood. Our aim was to assess the outcomes of a cohort of SUDD patients during a long-term follow up. One hundred eighty-five patients suffering from SUDD were identified from a large electronic database. Symptoms assessed were abdominal pain, bloating, bowel movement/day, each of which was scored using a visual analogic scale (VAS); the symptom score was calculated by considering the value of the worst symptom present during assessment. Another VAS was used to assess patients' quality of life (QoL). Patients were treated at the physician's discretion (with rifaximin, mesalazine, probiotics, spasmolytics) only when symptoms occurred during the follow up. Follow-up visit was performed every year or whenever patients consider it necessary. During the follow up (156 months, interquartile range 9-171), 47 patients were lost to follow up. Among these, 9 died from causes not related to SUDD. Acute diverticulitis occurred in 14 patients (7.6% of the overall population): 6 patients (3.2% of the overall population) underwent surgery, and 2 patients (1.1% of the overall population) died because of peritonitis. Both the symptom score and the QoL score were substantially unmodified during the study period. SUDD is an important disease able to affect patients significantly in the long term. Acute diverticulitis may sometimes occur in these patients, often leading to surgery with possible severe complications.
Sections du résumé
BACKGROUND
BACKGROUND
Symptomatic uncomplicated diverticular disease (SUDD) affects about 20% of patients who have diverticulosis. However, the natural history of SUDD is not yet completely understood. Our aim was to assess the outcomes of a cohort of SUDD patients during a long-term follow up.
METHODS
METHODS
One hundred eighty-five patients suffering from SUDD were identified from a large electronic database. Symptoms assessed were abdominal pain, bloating, bowel movement/day, each of which was scored using a visual analogic scale (VAS); the symptom score was calculated by considering the value of the worst symptom present during assessment. Another VAS was used to assess patients' quality of life (QoL). Patients were treated at the physician's discretion (with rifaximin, mesalazine, probiotics, spasmolytics) only when symptoms occurred during the follow up. Follow-up visit was performed every year or whenever patients consider it necessary.
RESULTS
RESULTS
During the follow up (156 months, interquartile range 9-171), 47 patients were lost to follow up. Among these, 9 died from causes not related to SUDD. Acute diverticulitis occurred in 14 patients (7.6% of the overall population): 6 patients (3.2% of the overall population) underwent surgery, and 2 patients (1.1% of the overall population) died because of peritonitis. Both the symptom score and the QoL score were substantially unmodified during the study period.
CONCLUSIONS
CONCLUSIONS
SUDD is an important disease able to affect patients significantly in the long term. Acute diverticulitis may sometimes occur in these patients, often leading to surgery with possible severe complications.
Identifiants
pubmed: 33654361
doi: 10.20524/aog.2020.0560
pii: AnnGastroenterol-34-208
pmc: PMC7903564
doi:
Types de publication
Journal Article
Langues
eng
Pagination
208-213Informations de copyright
Copyright: © 2021 Hellenic Society of Gastroenterology.
Déclaration de conflit d'intérêts
Conflict of Interest: None
Références
J Investig Med. 2019 Apr;67(4):767-770
pubmed: 30593541
Eur Rev Med Pharmacol Sci. 2013 Dec;17(23):3244-8
pubmed: 24338468
Aliment Pharmacol Ther. 2013 Oct;38(7):741-51
pubmed: 23957734
Dig Dis. 2007;25(3):252-9
pubmed: 17827951
Intern Emerg Med. 2012 Apr;7(2):133-7
pubmed: 21279478
J Clin Gastroenterol. 2016 Oct;50 Suppl 1:S9-S12
pubmed: 27622378
Br J Surg. 2010 Jun;97(6):952-7
pubmed: 20474006
Nat Rev Dis Primers. 2020 Mar 26;6(1):20
pubmed: 32218442
J Clin Gastroenterol. 2015 Mar;49(3):218-21
pubmed: 24583746
Clin Gastroenterol Hepatol. 2018 Jun;16(6):884-891.e1
pubmed: 28603053
Mediators Inflamm. 2019 Mar 14;2019:8328490
pubmed: 31001067
Eur J Clin Invest. 2013 Nov;43(11):1147-55
pubmed: 23992370
Clin Gastroenterol Hepatol. 2013 Dec;11(12):1609-13
pubmed: 23856358
Dig Dis. 2015;33(1):68-76
pubmed: 25531499
Am J Gastroenterol. 2019 Aug;114(8):1349-1350
pubmed: 31211706
Dis Colon Rectum. 2007 Sep;50(9):1460-4
pubmed: 17431721
Clin Gastroenterol Hepatol. 2018 Dec;16(12):2001-2002
pubmed: 30454933
J Gastrointestin Liver Dis. 2020 Jan 08;28(suppl. 4):57-66
pubmed: 31930220
Therap Adv Gastroenterol. 2016 Mar;9(2):213-28
pubmed: 26929783
Qual Life Res. 2015 Jan;24(1):163-79
pubmed: 25059533
Am J Gastroenterol. 2019 Mar;114(3):500-510
pubmed: 30839393
Gastroenterology. 2009 Mar;136(3):741-54
pubmed: 19166855